-
公开(公告)号：US20220002278A9
公开(公告)日：2022-01-06
申请号：US17075206
申请日：2020-10-20
Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES , SUZHOU INSTITUTE OF DRUG INNOVATION, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventor： Bing Zhou , Cheng Luo , Hualiang Jiang , Yaxi Yang , Lianghe Mei , Wenchao Lu , Senhao Xiao , Shijie Chen , Shili Wan , Gang Qiao , Rukang Zhang
IPC: C07D413/06 , C07D417/06 , C07D413/14 , C07D491/107 , C07D513/04 , C07D471/04 , C07D495/04 , C07D495/10
Abstract: Disclosed is a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by the general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising same and use thereof in the treatment of various HAT-related diseases or conditions.
-
公开(公告)号：US20250059219A1
公开(公告)日：2025-02-20
申请号：US18556165
申请日：2022-03-25
Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES , SUZHOU QINGYA QIRUI BIOTECHNOLOGY CO., LTD.
Inventor： Jianhua SHEN , Zhiyuan ZHU , Xiaomei LI , Kai WANG , Jia LIU
IPC: C07F9/655 , A61K31/365 , A61K31/665 , A61P1/00 , A61P1/16 , A61P11/00 , A61P19/02 , A61P25/28 , A61P35/00 , A61P35/02 , C07D307/33
Abstract: Disclosed in the present invention are a lignan derivative, a preparation method therefor and the use thereof. The structure of the lignan derivative is as shown in a formula I, wherein in the formula, the definition of each substituent is as described in the description and claims. The lignan derivative of the present invention can be used as an inhibitor of mitochondrial respiratory chain complex I to inhibit mitochondrial oxidative phosphorylation and ATP generation, and can also be used for preventing and/or treating diseases associated with the elevated activity or expression of the mitochondrial respiratory chain complex I or enhanced mitochondrial oxidative phosphorylation.
-
公开(公告)号：US20240150300A1
公开(公告)日：2024-05-09
申请号：US18278063
申请日：2022-02-18
Inventor： Youhong HU , Meiyu GENG , Daqiang LI , Aijun SHEN , Zhuo ZHANG , Yalei LI , Huajie YANG , Hongchun LIU , Hanyue ZHONG , Jian DING
IPC: C07D237/14 , A61P35/00 , A61P35/02 , C07C67/00 , C07C67/10 , C07D401/04 , C07D403/04
CPC classification number: C07D237/14 , A61P35/00 , A61P35/02 , C07C67/00 , C07C67/10 , C07D401/04 , C07D403/04
Abstract: The present invention relates to an S-configuration-containing amino benzamide pyridazinone compound, a preparation method therefor, and a pharmaceutical composition and application thereof. Specifically, the present invention relates to a compound represented by the following general formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition and application thereof. The S-configuration compound of the present application has very strong binding activity on class I histone deacetylase (HDAC1), and shows inhibitory activity on in-vitro proliferation of various tumor cells.
-
4.发明公开公开(公告)号：US20240059676A1
公开(公告)日：2024-02-22
申请号：US18267298
申请日：2021-12-10
IPC: C07D403/10 , C07D413/10 , C07D471/04 , A61P3/06
CPC classification number: C07D403/10 , C07D413/10 , C07D471/04 , A61P3/06
Abstract: The present invention relates to a thyroid hormone receptor β selective agonist compound represented by formula I, a pharmaceutical composition and use thereof. The compound improves the selectivity to THR-α and the druggability of the compound while maintaining good THR-β agonistic activity, and shows a certain activity in in vivo pharmacological experiments.
-
公开(公告)号：US11873292B2
公开(公告)日：2024-01-16
申请号：US16306751
申请日：2017-06-02
Inventor： Hong Liu , Jia Li , Wei Zhu , Yubo Zhou , Jiang Wang , Mingbo Su , Shuni Wang , Wei Xu , Chunpu Li , Weijuan Kan , Hualiang Jiang , Kaixian Chen
IPC: C07D403/12 , C07D215/58 , C07D209/04 , C07D215/00 , C07D487/04 , C07D209/08 , C07D401/12 , C07D405/12 , A61P35/00
CPC classification number: C07D403/12 , A61P35/00 , C07D209/04 , C07D209/08 , C07D215/00 , C07D215/58 , C07D401/12 , C07D405/12 , C07D487/04 , Y02P20/55
Abstract: The present invention relates to the fields of medicinal chemistry and pharmacotherapy, and specifically relates to the chemical compound of formula (I), and its racemate, R-isomer, S-isomer, pharmaceutically acceptable salt, and mixtures thereof, as well as its method for preparation, a pharmaceutical composition containing said chemical compound, and use as a lysine-specific demethylase 1 (LSD 1) inhibitor. The cyclopropylamine chemical compound to which the present invention relates may be used in the treatment of cancer.
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20230219993A1
公开(公告)日：2023-07-13
申请号：US17996430
申请日：2021-04-16
Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES , WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCE , XINJIANG TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY, CHINESE ACADEMIY OF SCIENCES , VIGONVITA LIFE SCIENCES CO., LTD.
Inventor： Yuanchao XIE , Gengfu XIAO , Yang HE , Leike ZHANG , Heji Akber AISA , Hualiang JIANG , Jingshan SHEN
CPC classification number: C07H7/06 , A61P31/14 , A61P31/16 , C07B2200/05
Abstract: The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia
(COVID-19) and other related diseases caused by 2019 novel coronavirus infection.-
公开(公告)号：US11555009B2
公开(公告)日：2023-01-17
申请号：US16490186
申请日：2018-03-01
Inventor： Caiguang Yang , Yue Huang , Ze Dong , Tao Zhang , Hongjiao Xu
IPC: C07C229/58 , A61P35/00 , C07D261/08 , A61K31/42 , A61K31/196 , C07D231/12 , A61K31/415 , C07D213/38 , A61K31/4418 , C07D333/20 , A61K31/381 , C07D239/26 , A61K31/505 , C07D333/40 , C07D239/42 , C07D211/70 , C07D209/14 , A61K31/404 , C07D233/64 , A61K31/4164 , C07D257/04 , A61K31/41 , C07D407/12 , A61K31/422 , A61K31/4245 , C07D401/12 , A61K31/4439 , A61K31/5355 , C07C227/16
Abstract: The invention provides 2-(substituted phenylhetero) aromatic formate FTO inhibitors, a preparation method thereof, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted phenylhetero) aromatic formate compound represented by the following formula (I), and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, which can be used as an FTO targeting inhibitor for treating diseases associated with FTO targets, including obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's diseases, and cancers such as breast cancers, small-cell lung cancers, human bone marrow rhabdomyosarcoma, pancreatic cancer, malignant glioblastoma and the like.
-
公开(公告)号：US20220356202A1
公开(公告)日：2022-11-10
申请号：US17860468
申请日：2022-07-08
Applicant: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventor： Meiyu Geng , Jian Ding , Zhenqing Zhang , Zhongping Xiao , Xiaoguang Du , Xianliang Xin
IPC: C07H15/04 , A61P25/28 , A61K31/7032 , A61K31/715 , C08B37/00
Abstract: The present invention relates to a mannuronic diacid oligosaccharide composition, comprising a mannuronic diacid of Formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 9, m is 0, 1 or 2, and m′ is 0 or 1, and wherein the total weight of mannuronic diacids wherein n=1-5 is 80-95% of the total weight of the composition, and the ratio of the total weight of mannuronic diacids wherein n=1-3 to the total weight of mannuronic diacids wherein n=4-7 is between 1.0 and 3.5.
-
公开(公告)号：US11464794B2
公开(公告)日：2022-10-11
申请号：US17256853
申请日：2019-06-28
Applicant: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventor： Meiyu Geng , Zhenqing Zhang , Yingshen Jin , Zhongping Xiao , Jian Ding
IPC: A61K31/702 , A61P25/28 , A61P29/00
Abstract: The present invention relates to an alginic oligosaccharic diacid composition comprising a mannuronic diacid of Formula (IV) or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 9, m is selected from 0, 1 or 2, m′ is selected from 0 or 1, and wherein the total weight of alginic oligosaccharic diacid wherein n=1-5 accounts for more than 60% of the total weight of the composition; the total weight of guluronic acids accounts for less than 50% of the total weight of the composition.
-
公开(公告)号：US11406651B2
公开(公告)日：2022-08-09
申请号：US17256738
申请日：2019-06-28
Applicant: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventor： Meiyu Geng , Xianliang Xin , Xiaoguang Du , Zhenqing Zhang , Jian Ding
IPC: A61K31/702 , A61P25/28
Abstract: The present invention relates to the application of mannuronic diacid oligosaccharide composition in the treatment of vascular dementia.
-
-
-
-
-
-
-
-
-
Search Results
249
records
(took 0.027 seconds)
